Clinical trials: Open Angle Glaucoma -Ocular Hypertension
Open Angle Glaucoma, Ocular Hypertension
Next Generation Rocklatan
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
- Trial name
- NCT06441643
- Testing
- AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 426 people
- Sponsor
- Alcon Research
Glaucoma Open-Angle Primary, Ocular Hypertension
GLAUcoma Diagnostic and Imaging Analysis (GLAUDIA) Study
This observational study aims to identify early diagnostic markers of glaucomatous damage by combining functional and structural assessments.
- Trial name
- GLAUDIA (NCT07210216)
- Volunteers
- 60 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Glaucoma, Open-Angle, Pseudoexfoliation Glaucoma
Optimal Treatment Protocol for Selective Laser Trabeculoplasty - Repeat Trial
Glaucoma is a common eye disease that can lead to blindness. The only known way to reduce the rate of disease progression is by reducing the pressure in the eye (the intraocular pressure, IOP).
- Conditions
- Glaucoma, Open-Angle, Pseudoexfoliation Glaucoma, Ocular Hypertension
- Trial name
- OSLT-R (NCT05159960)
- Testing
- SLT
- Where
- 2 sites in Sweden
- Volunteers
- 400 people
- Sponsor
- Vastra Gotaland Region
Open Angle Glaucoma, Ocular Hypertension
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma.
- Trial name
- Denali (NCT04630808)
- Testing
- NCX 470 0.1%, Latanoprost 0.005%
- Where
- 88 sites in United States, China
- Volunteers
- 696 people
- Sponsor
- Nicox Ophthalmics, Inc.
Glaucoma Open-Angle Primary, Ocular Hypertension
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 [0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
- Trial name
- NCT05913232
- Testing
- H-1337 0.6%, H-1337 1.0%, Timolol 0.5%
- Where
- 9 sites in United States
- Volunteers
- 201 people
- Sponsor
- D. Western Therapeutics Institute, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension…
- Trial name
- TRITON (NCT03850782)
- Testing
- Bimatoprost (SR)
- Where
- 108 sites in United States, Argentina and 14 more
- Volunteers
- 515 people
- Sponsor
- AbbVie
Open-angle Glaucoma, Ocular Hypertension
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
- Trial name
- ARGOS (NCT04647214)
- Where
- 39 sites in United States
- Volunteers
- 220 people
- Sponsor
- Allergan
Open Angle Glaucoma, Ocular Hypertension
A Study to Assess an Automated Laser Device for Direct Selective Laser Trabeculoplasty
Glaucoma is an eye disease that results in damage to the optic nerve that progresses over time. One of the main risk factors in glaucoma is an increase in intraocular pressure, caused by a build-up of fluid in the eye.
- Trial name
- GLAUrious (NCT03750201)
- Testing
- Direct Selective Trabeculoplasty, Selective Trabeculoplasty
- Where
- 8 sites in Israel, Italy and 1 more
- Volunteers
- 201 people
- Sponsor
- BelkinVision
Primary Open Angle Glaucoma, Glaucoma
A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients
Background Glaucoma is a progressive optic neuropathy characterized by elevated intraocular pressure (IOP), leading to irreversible vision loss.
- Conditions
- Primary Open Angle Glaucoma, Glaucoma, Primary Open Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT07076303
- Testing
- Direct Selective Laser Trabuloplasty
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Brian Shafer
Open Angle Glaucoma, Ocular Hypertension
Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
- Trial name
- Mont Blanc (NCT04445519)
- Testing
- NCX 470 0.065% (initial phase of trial), Latanoprost 0.005% (initial phase of trial), NCX 470 0.1% (initial phase of trial)
- Where
- United States
- Volunteers
- 691 people
- Sponsor
- Nicox Ophthalmics, Inc.
Glaucoma, Open-Angle, Normal Tension Glaucoma
Investigation of Neurovascular Coupling in Glaucoma Patients and Healthy Subjects
Glaucoma is characterized by a progressive loss of retinal ganglion cells (RGCs) leading to optic nerve head (ONH) damage and associated visual field defects.
- Conditions
- Glaucoma, Open-Angle, Normal Tension Glaucoma, Ocular Hypertension
- Trial name
- NCT03870230
- Testing
- Fourier Domain Doppler Optical Coherence Tomography (FDOCT), Dynamic Vessel Analyzer (DVA), Pattern Electroretinography (pERG)
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Glaucoma, Open-Angle, Ocular Hypertension
To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
To compare the efficacy and safety of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Trial name
- NCT04944290
- Testing
- Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
- Where
- United States
- Volunteers
- 447 people
- Sponsor
- Padagis LLC
Glaucoma, Primary Open Angle, Ocular Hypertension
Safety and IOP-Lowering Effects of WB007
The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study.
- Trial name
- NCT04149899
- Testing
- WB007 0.05%, WB007 0.15%, WB007 0.4%
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bausch & Lomb Incorporated
Open Angle Glaucoma or Ocular Hypertension
OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects
It is a phase III, multi-center, randomized, single-blind (to evaluator), parallel, and positive-controlled clinical trial evaluating the efficacy and safety of OPC-1085EL in the treatment of primary open angle glaucoma or ocular…
- Trial name
- NCT05583474
- Testing
- OPC-1085EL, 0.005% Latanoprost
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Otsuka Beijing Research Institute
Glaucoma Open-Angle Primary, Ocular Hypertension
Open-Label Study of Safety of H1337 in Healthy Volunteers
The trial will evaluate the safety of one dose regimen of H-1337 [1% twice daily (b.i.d.)] in both eyes in healthy volunteers.
- Trial name
- NCT06572397
- Testing
- H-1337 1.0%
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- D. Western Therapeutics Institute, Inc.
Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.
- Conditions
- Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension (OHT)
- Trial name
- NCT06016972
- Testing
- Experimental: QLS-111 ophthalmic solution, (0.015%), Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Qlaris Bio, Inc.
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.
- Conditions
- Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
- Trial name
- NCT06249152
- Testing
- QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Qlaris Bio, Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
Evaluating the safety and tolerability of QLS-101 versus timolol maleate ophthalmic solution in glaucoma or ocular hypertension.
- Trial name
- NCT04830397
- Testing
- QLS-101, Timolol Maleate
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Qlaris Bio, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
Phase III study to compare the safety and efficacy of intraocular implants containing travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (timolol) in reducing elevated intraocular pressure…
- Trial name
- NCT03519386
- Testing
- G2-TR intraocular implant containing travoprost
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle, Ocular Hypertension
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
Phase III study to compare the safety and efficacy of intraocular implants containing Travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (Timolol) in reducing elevated intraocular pressure…
- Trial name
- NCT03868124
- Testing
- G2-TR intraocular implant containing travoprost
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- Glaukos Corporation